Tag: Prescription Drugs

Statement of Commissioner Christine S. Wilson in the Matter of Pfizer Inc./Mylan N.V.

Date

October 30, 2020

Christine S. Wilson, Former Commissioner

Matter Number

191 0182

Statement of Commissioner Christine S. Wilson in the Matter of Pfizer Inc./Mylan N.V. (39.81 KB)

Dissenting Statement of Commissioner Rohit Chopra Joined by Commissioner Rebecca Kelly Slaughter in the Matter of Pfizer Inc./Mylan N.V. (93.83 KB)

Dissenting Statement of Commissioner Rohit Chopra Joined by Commissioner Rebecca Kelly Slaughter in the Matter of Pfizer Inc./Mylan N.V.

Date

October 30, 2020

Rohit Chopra, Former Commissioner

Matter Number

191 0182

AbbVie Inc. and Allergan plc, In the Matter of

Pharmaceutical companies AbbVie Inc. and Allergan plc have agreed to divest assests to settle Federal Trade Commission charges that AbbVie's proposed $63 billion acquisition of Allergan would violate federal antitrust law. On Sept. 4, 2020, the Commission announced the final consent agreement in this matter.

Type of Action

Administrative

Last Updated

September 4, 2020

FTC Matter/File Number

191 0169

Case Status

Pending

Federal Register Notice

Elanco Animal Health and Bayer Animal Health; Analysis of Agreement Containing Consent Orders To Aid Public Comment

Date

July 21, 2020

FTC Approves Final Order Settling Charges that Danaher Corporation’s Acquisition of GE Biopharma Was Anticompetitive

Date

May 29, 2020

Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Danaher Corporation’s acquisition of GE Biopharma would likely reduce competition in...

Federal Register Notice

AbbVie Inc. and Allergan plc; Analysis of Consent Order To Aid Public Comment

Date

May 12, 2020

Statement of Chairman Joseph J. Simons, Commissioner Noah J. Phillips and Commissioner Christine S. Wilson Concerning the Proposed Acquisition of Allergan plc by AbbVie Inc. (424.16 KB)

Statement of Chairman Joseph J. Simons, Commissioner Noah J. Phillips and Commissioner Christine S. Wilson Concerning the Proposed Acquisition of Allergan plc by AbbVie Inc.

Date

May 5, 2020

Joseph J. Simons, Former Chairman;

Noah Joshua Phillips, Former Commissioner;

Christine S. Wilson, Former Commissioner

Matter Number

191 0169

Dissenting Statement of Commissioner Rohit Chopra In the Matter of AbbVie Inc. and Allergan plc

Date

May 5, 2020

Rohit Chopra, Former Commissioner

Matter Number

191 0169

Dissenting Statement of Commissioner Rohit Chopra in the Matter of Abbvie Inc. and Allergan plc [Redacted] (184.39 KB)

Dissenting Statement of Commissioner Rebecca Kelly Slaughter Regarding the Proposed Acquisition of Allergan plc by AbbVie Inc.

Date

May 5, 2020

Rebecca Kelly Slaughter, Commissioner

Matter Number

191 0169

Dissenting Statement of Commissioner Rebecca Kelly Slaughter in the Matter of AbbVie and Allergan (405.02 KB)

Six More States Join FTC and NY Attorney General’s Case Against Vyera Pharmaceuticals, Martin Shkreli, and Other Defendants

Date

April 14, 2020

The Federal Trade Commission has filed an amended complaint in federal court against Vyera Pharmaceuticals, LLC, adding six new states as co-complainants. The FTC filed the original complaint jointly...

FTC Imposes Conditions on Danaher Corporation’s Acquisition of GE Biopharma

Date

March 19, 2020

Danaher Corporation has agreed to divest assets to settle Federal Trade Commission charges that its proposed $21.4 billion acquisition of General Electric’s biopharmaceutical business, GE Biopharma...

Concurring Statement of Commissioner Rohit Chopra in Federal Trade Commission; and State of New York v. Vyera Pharmaceuticals, LLC; Phoenixus AG; Martin Shkreli; and Kevin Mulleady (140.28 KB)

Concurring Statement of Commissioner Rohit Chopra in Federal Trade Commission; and State of New York v. Vyera Pharmaceuticals, LLC; Phoenixus AG; Martin Shkreli; and Kevin Mulleady

Date

January 27, 2020

Rohit Chopra, Former Commissioner

Concurring Statement of Commissioner Rebecca Kelly Slaughter in Federal Trade Commission; and State of New York v. Vyera Pharmaceuticals, LLC; Phoenixus AG; Martin Shkreli; and Kevin Mulleady (32.62 KB)

Concurring Statement of Commissioner Rebecca Kelly Slaughter in Federal Trade Commission; and State of New York v. Vyera Pharmaceuticals, LLC; Phoenixus AG; Martin Shkreli; and Kevin Mulleady

Date

January 27, 2020

Rebecca Kelly Slaughter, Commissioner

FTC and NY Attorney General Charge Vyera Pharmaceuticals, Martin Shkreli, and Other Defendants with Anticompetitive Scheme to Protect a List-Price Increase of More Than 4,000 Percent for Life-Saving Drug Daraprim

Date

January 27, 2020

The Federal Trade Commission has filed a complaint in federal court against Vyera Pharmaceuticals, LLC , alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug...

Closing Letters

Roche Holding Ltd./Spark Therapeutics, Inc.

Date

December 16, 2019

Matter Number

191 0086

Closing Letter to Counsel for Spark Therapeutics, Inc. (88.48 KB)

Closing Letter to Counsel for Spark Therapeutics, Inc. (40.23 KB)

Closing Letter to Counsel for Roche Holding Ltd. (40.35 KB)

Statement of the Federal Trade Commission in the matter of Roche Holding/Spark Therapeutics

Date

December 16, 2019

Joseph J. Simons, Former Chairman;

Noah Joshua Phillips, Former Commissioner;

Rohit Chopra, Former Commissioner;

Rebecca Kelly Slaughter, Commissioner;

Christine S. Wilson, Former Commissioner

Matter Number

191 0086

Statement of the Federal Trade Commission in the matter of Roche Holding/Spark Therapeutics (213.41 KB)

Federal Trade Commission Closes Investigation of Roche Holding AG’s Proposed Acquisition of Spark Therapeutics, Inc.

Date

December 16, 2019

The Federal Trade Commission has closed its investigation into Roche Holding AG’s proposed acquisition of Spark Therapeutics, Inc. According to a Commission Statement , after an exhaustive, 10-month...